Ferroquine is primarily used in the treatment of malaria, particularly for cases caused by Plasmodium falciparum, which is known for its resistance to conventional antimalarial drugs. Its unique structure combines a ferrocene moiety with a chloroquine-like component, enhancing its efficacy against drug-resistant strains. In clinical settings, Ferroquine is often administered in combination with other antimalarial agents to improve treatment outcomes and reduce the risk of resistance development. It is particularly valuable in regions where malaria is endemic and resistance to standard therapies is prevalent. Research has also explored its potential in treating other parasitic infections, though its primary application remains focused on malaria. Its mechanism of action involves disrupting the parasite's digestive processes, leading to its death. Overall, Ferroquine represents a significant advancement in antimalarial therapy, offering hope for more effective management of this life-threatening disease.